Skip to main content

CORRECTED: Tranzyme to Produce Cell Lines for Gentris with PGx Applications

This article has been corrected. In a previous version, the name "Gentris," was misspelled and the headline was unclear.


NEW YORK, June 24 (GenomeWeb News) - North Carolina biotechnology companies Tranzyme Pharma and Gentris said today that they are collaborating to develop cell lines intended to serve as genetic controls for diagnostic assays used to gauge patients' responses to drug treatments.


Morrisville-based Gentris will provide Tranzyme, located in ResearchTrianglePark, with genetic sequences relating to rare, clinically relevant alleles that are implicated in the metabolism of therapeutic compounds, according to an official company statement. Tranzyme will then use its functional biology and gene delivery technology, called TExT, to create recombinant human cell lines expressing the genetic sequences. Financial terms of the deal were not disclosed.


In addition, the companies said that they will jointly own the cell lines, and may eventually enter into an additional agreement to commercialize them as genetic controls for FDA-approved diagnostic assays.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.